This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.
Dentsply International (XRAY) Q2 Earnings Top Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 6.45% and -2.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Dentsply Sirona (XRAY)
by Zacks Equity Research
Dentsply Sirona (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.
Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?
by Zacks Equity Research
Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.
Why Dentsply (XRAY) Could Beat Earnings Estimates Again
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) projects operating income within $460-$465 million for the second quarter.
GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
by Zacks Equity Research
Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.
Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?
by Zacks Equity Research
In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) aims at product innovation through R&D.
AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.
Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
Dentsply International (XRAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand
by Zacks Equity Research
It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.
ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Masimo's (MASI) recent developments likely to show on second-quarter results.
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
Align Technology (ALGN) Beats on Q2 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies.
Integra Lifesciences' (IART) Earnings Top Estimates in Q2
by Zacks Equity Research
We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.
Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View
by Zacks Equity Research
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.